AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04932018 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Community of Support
Description: The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
Study NCT04932018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Community of Support
Description: The 6-month virtual community will consist of self-directed learning modules that will vary in content from worker and family relationships, collaboration and skill acquisition to self-care habits; problem-solving; monthly sessions will include a positive psychology exercise.
Study NCT04932018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship Incubator
Description: The 6-month incubator intervention will consist of monthly interactive time with an assigned study facilitator/farmer mentor.
Study NCT06357598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg, ivgtt, day 1 of each 21-day cycle, neoadjuvant therapy : 2-4 cycles; Adjuvant therapy: 16cycles at most.
Study NCT06357598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Non-squamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Description: Pemetrexed: 500 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles. Nab-paclitaxel: 260mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
Study NCT06357598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin or Cisplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 ivgtt on day 1 of each 21-day cycle for 2-4 cycles.~Cisplatin: 75 mg/m\^2, ivgtt, day 1 of each 21-day cycle, 2-4 cycles.
Study NCT06357598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be done within the 4th-6th week from day 1 the last cycle of neoadjuvant treatment.
Study NCT05567692 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OGTT
Description: Oral Glucose Tolerance Test
Study NCT05567692 — intervention group
Intervention type: OTHER
Intervention: HbA1c
Description: HbA1c measurement
Study NCT05567692 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Follow-up questionnaire
Study NCT06392503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: different diagnostic models
Description: the patients were screened by different diagnostic models
Study NCT05047510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-GPC3-IRDye800CW
Description: Drug Injection: Anti-GPC3-IRDye800CW
Study NCT06385223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Beam F3 targeted accelerated iTBS
Description: Magpro X100, Axilium Cobot, Localite camera
Study NCT06385223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized connectome-guided accelerated iTBS
Description: Magpro X100, Axilium Cobot, Localite camera
Study NCT05700045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: each side dexmedetomidine 0.5ug/kg TAP block
Study NCT06417944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scoliosis study form
Description: Scoliosis study form consisting of clinical and radiological measurements of patients aged 10-18 years who applied to the outpatient clinic with spine deformity will be filled in detail.
Study NCT06417944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Scoliosis X-ray (orthorontgenogram)
Description: Patients whose Adam's forward bending test and clinical evaluation results are compatible with scoliosis, scoliosis graphy are requested. (Adams test (forward bending test) (+) was measured by Bunnell scoliometer (scoliosis assessment tool) and ATR (angle of trunk rotation angle) values were 5 degrees in those with BMI (Body Mass Index) above 85%. If it is below 85% and above 7 degrees, patients who meet the inclusion criteria will be included in the study by filling out an informed consent form and a scoliosis film will be requested.).Coronal, sagittal balance; coronal and sagittal Cobb angles will be measured from posterior-anterior (PA) and lateral scoliosis radiographs.
Study NCT06417944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary function test
Description: Pulmonary function tests (PFTs) are noninvasive tests that show how well the lungs are working. The tests measure lung volume, capacity, rates of flow, and gas exchange. This information can help your healthcare provider diagnose and decide the treatment of certain lung disorders. We will use handheld spirometry device for measurement. Three measurements will be made. In these three measurements; FEV1(Forced Expiratory Volume In One Second)(L), FEV1 (%predicted), FVC (Forced Vital Capacity) (L), FVC (%predicted), FEV1/FVC (%) and FEV1/FVC (%predicted) will be evaluated. The arithmetic average of the results of these three measurements will be taken.
Study NCT06417944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonographic Measurement
Description: Diaphragm thickness will be measured in the supine position with a 6-14 Mhz lineer, conventional ultrasound probe (Mindray DC-8, Shenzen Mindray Bio-Medical Electronics CO. LTD.,P.R. China) at the end of inspiration and expiration from the intercostal space on the anterior axillary line. The measurements will be evaluated by making three measurements from the right 8-9. intercostal space where the diaphragm is best visualized. End-expiratory (Forced residual capacity-FRC) (centimeter- cm), end-inspiratory (Total Lung Capacity) (centimeter-cm) and thickening rate (%) (thickness TLC / thickness FRC) will be evaluated three times and the arithmetic average of these three measurements will be taken.
Study NCT06417944 — intervention group
Intervention type: PROCEDURE
Intervention: Three-dimensional Exercise (BSPTS Schroth Exercise)
Description: It only provides outpatient treatment, but it has different practices, intensive or regular, depending on local and external patients. For local patients, it is applied once a week, accompanied by a therapist, and the treatment duration is determined according to the patient's condition. In patients coming from outside; It can be continued as 2 hours a day for 10 days, then as additional treatment for 1-2 weeks for 3-6 months depending on the patient's condition. I In regular treatment; 30 sessions of 90 minutes group treatment, the first 8 sessions are carried out under the supervision of a therapist for a shorter period of time.~We will give 10 sessions of BSPTS Schroth exercises, either outpatient or inpatient. After 10 sessions of the Schroth exercise program, the home program will continue two months after outpatient/inpatient schroth exercise(Home program: 5 days/week, 45-60 minutes for all patients).
Study NCT06417944 — intervention group
Intervention type: PROCEDURE
Intervention: Home Exercise
Description: In the home exercise program; daily living activities, neutral pelvis exercises, coronal balance exercises, rotational angular breathing exercises and axial elongation exercises were taught by the physiotherapist in one session. A total of 10-week home exercise program was planned, with exercises to be performed twice a week for the first two weeks, once every 15 days for 1 month (twice in one month), and then once a month.
Study NCT05377658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: 10 mg/kg via intravenous infusion on Day 1 of each 21-day cycle.
Study NCT05377658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 260mg/m\^2 via intravenous infusion on Day 1 of each 21-day cycle.
Study NCT05377658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min via intravenous infusion on Day 1 of each 21-day cycle.
Study NCT06514664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using Probiotic Toothpaste
Description: Scaling and root planing (Phase 1 = non-surgical periodontal treatment) are performed in all patient groups.~Depending on the study groups, regular or probiotic toothpaste will be used. Toothpaste is instructed to be used twice a day
Study NCT06321198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iMSC
Description: Subjects will receive 4 or more times of iMSC injection
Study NCT05536752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102/Placebo
Description: Capsules
Study NCT05536752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QA102
Description: Capsules
Study NCT05536752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study NCT05843552 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention, this is an observational study
Study NCT06099470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time synchronized telerehabilitation program (STP).
Description: patient education, core stabilization exercises, strengthening exercises, stretching exercises
Study NCT06099470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-recording non-synchronized telerehabilitation program (NSTP)
Description: Pre-recording non-synchronized telerehabilitation program (NSTP)
Study NCT06099470 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home non-supervised control group (HCG)
Description: Home non-supervised control group (HCG)
Study NCT06424158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Description: Massage therapy (MT) has been proven as an alternative non-opioid pain management intervention, particularly towards reducing pain, diminishing depression, improving immune function, and increasing alertness in the adult population. MT raises the temperature of local tissues, dilates capillaries, accelerates the circulation of blood and lymph, promotes the absorption of local tissue metabolism and mass inflammation, improves the nutritional supply of surrounding muscle groups, promotes their growth and development, and relieves pain.
Study NCT05824039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tea infusion
Description: Tea infusion: The aerial parts of the medicinal plant were dried, then, they were powdered in a rotating knife grinder. The herbs were taken as tea infusion by the oral route. The powder was added to 100 ml of boiling water and the tea infusion was taken once time a day at the bed time and it was repeated for 10 days.
Study NCT05459324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD Study Electrode
Description: The HD Study Electrode is an array of 8 columns of stimulation contacts arranged in 8 rows with a low-volume electrode body. This array of stimulation electrodes contact patterns of bi-poles and tri-poles may be applied to the spinal cord for assessment of dermatomal selective stimulation patterns.
Study NCT05491954 — intervention group
Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring
Study NCT05192551 — intervention group
Intervention type: OTHER
Intervention: Bowel-prep (Plenvu as experimental arm)
Description: In this study we will investigate the efficacy and patient satisfaction of the,in Sweden recently approved and introduced low-dose, Peg-based bowel-prep Plenvu in comparsion with the standard bowel-preps used i today's clinical routine
Study NCT05328791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary and mindfulness intervention
Description: Dietary intervention: Preparation and follow-up of diet program~Mindfulness intervention: Implementation of cognitive stress reduction program
Study NCT05030974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: SARS-CoV-2 vaccination
Study NCT05030974 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad26.COV2.S vaccine
Description: SARS-CoV-2 vaccination
Study NCT05000177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute computer typing task
Description: The subject sits in front of a computer screen and perform computer typing tasks for 30 minutes. The same computer table and chair were used for all subjects. The height of the table and screen, and the distance of the keyboard from the subject were adjusted according to their familiar and comfortable position.
Study NCT05000177 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute rest
Description: Rest for 30 minutes
Study NCT04248920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic to Community Education Program
Description: The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
Study NCT04248920 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinic to Community Education Program
Description: The C2C program aims to improve participants' knowledge of epilepsy and access to services and to provide support. Participants randomized to the intervention group will complete the C2C program. They will receive an in-person one-on-one 60-minute education session and will be introduced to, and encouraged to participate in, the programs and support services that are provided by Epilepsy Southwestern Ontario (ESWO).
Study NCT04942015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Honghuaruyi Wan
Description: Honghuaruyi Wan is the traditional Tibetan prescription, clinical research has proved that Honghuaruyi Wan can significantly reduce risk mouse dysmenorrhea caused by oxytocin, improve dysmenorrhea model of mice body torsion times and improve the estrogen and progestogen operator Netherlands rat pituitary estradiol and prolactin level, at the same time also can reduce the amount of TNF alpha, thus improving endometriosis dysmenorrhea.(Pill (15 pills/plate ×2 plates/box))
Study NCT04942015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Honghuaruyi Wan
Description: Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
Study NCT05401812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid therapy
Description: Betamethasone, dexamethasone, or methylprednisolone
Study NCT05545995 — intervention group
Intervention type: OTHER
Intervention: embryo selection
Description: The basis of embryo seletion for transfer: morphological or genetic after non-invasive PGT-A
Study NCT05911724 — intervention group
Intervention type: OTHER
Intervention: Group I Healthy
Description: Healthy Subjects
Study NCT05911724 — intervention group
Intervention type: DRUG
Intervention: CAD-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Description: Group II: Stable Angina Patients
Study NCT05911724 — intervention group
Intervention type: DRUG
Intervention: HF-Empagliflozin 10 mg once daily for 6 months before the beginning of the study
Description: Group III: Heart Failure Patients
Study NCT05527184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN151
Description: IMGN151 is an antibody-drug conjugate (ADC).
Study NCT05088083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
Description: After predilation, using drug-coated balloon catheter to cover the whole treated segment
Study NCT05449379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory training with the use of resistance set on respiratory muscle trainer
Description: Performing respiratory training with resistance set on respiratory trainer.
Study NCT05449379 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Respiratory training without resistance set on respiratory muscle trainer
Description: Performing respiratory training with no resistance set on respiratory trainer
Study NCT04407650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or >6.2),~* Recruitment centre
Study NCT04407650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Patients will be randomized to each intervention using minimisation:~* BMI category (Overweight/Obese),~* Previous history of GDM,~* Disease severity (baseline fasting glucose ≤6.2 or >6.2),~* Recruitment centre
Study NCT06223256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBL-028
Description: Intravenous infusion (IV), once every two weeks (one treatment cycle is 4 weeks).
Study NCT05704543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.
Study NCT05704543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Extended-Release Injection
Description: Administered as a subcutaneous injection.
Study NCT06264219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome restoration - FMT
Description: Pathogen-free microbiota from maternal stool sample is transferred from mother to infant.
Study NCT06264219 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Microbiome restoration - FVT
Description: Sterile-filtered and ultracentrifuged FMT, containing only viruses, is transferred from mother to infant.
Study NCT06264219 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive solution buffer
Study NCT06264219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal birth, untreated control
Description: No intervention. This group is for secondary outcomes comparisons.
Study NCT05627531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Medicine
Description: Intervention group completes pre- and post-intervention measures, composition book and guided reading, discussion, and writing with narrative medicine coordinator.
Study NCT05643183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Astmakompas
Description: The Astmakompas platform consists of a patient app, a portal for HCPs, and a wireless spirometer connected to the patient app. The patient app combines monitoring with self-management tools, and provides a portal to present these data as well as to communicate with their HCP. Patients' monitoring data is linked to their personalized digital action plan, including self-management strategies and treatment recommendations based on the latest international treatment guidelines. The action plan aims to increase patients' awareness of their symptoms and/or the severity of their symptoms, as well as their corresponding adverse effects. When patients' monitoring results show a deterioration of asthma control, HCPs receive smart notifications. Patient data can thereby serve as direct input in the consultations with the HCP, or they can proactively offer as-needed support. Patients are able to ask non-critical asthma-related questions to their HCP through a chat function of the application.
Study NCT06489821 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Stereotactic body radiotherapy in 5 fractions (body) or 2 or 4 fractions (spine) plus continuation of first line systemic therapy
Study NCT06289608 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No dental intervention was made. Only a clinical examination
Study NCT04889469 — intervention group
Intervention type: PROCEDURE
Intervention: Breast reduction
Description: Procedure to remove excess fat, tissue and skin from the breasts.
Study NCT05725811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic foam rolling
Description: The foam roller will be in contact with the muscle being tested and the patient will exert a load until they feel a slight pain. In this way, the patient performs a self-massage in the direction of the muscle fibers.
Study NCT03757897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
Study NCT04748341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedagogical Framework (Learn, See, Practice, Prove, Do, and Maintain)
Description: The Learn, See, Practice, Prove, Do, and Maintain (LSPPDM) pedagogy is acting as a guiding path for educators in teaching and learning procedural skills. It is synthesized after intensely reviewing the literature comprises steps. In the 1st step, learners learn through didactic lectures, further proceeding to see procedural videos. The 3rd step, Practice expose learners to perform the skill on a simulator. In the 4th step Prove the learner proves the skill. The 5th step Do comprise real-life exposure through the clinical rotation. Then, finally the 6th stepMaintain the learner maintains skill supplemented with simulation as needed.
Study NCT04748341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Method
Description: The traditional method group learns through 2-step method.~1. didactic lectures on neonatal resuscitation were delivered.~2. Practice skill on mannequins
Study NCT06069245 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: 80mg of MitoQ taken in one dose on one occasion.
Study NCT04813133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized Lifestyle Modification Program
Description: Synchronization of dietary intake with circadian rhythm of the body.
Study NCT04813133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synchronized Lifestyle Modification Program and Physiotherapy
Description: Synchronization of dietary intake with circadian rhythm of the body along with Physiotherapy ( Aerobics, flexibility, resistance and balance exercises.)